Advertisement

Myeloproliferative Neoplasms

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry

Abstract

Myeloproliferative neoplasms (MPNs) formerly known as chronic myeloproliferative disorders are clonal haemopoietic stem cell disorders characterised by excessive production of mature blood cells. The classic MPNs are polycythaemia vera (PV), essential thrombocythaemia (ET), primary myelofibrosis (PMF) (Phi-negative) and chronic myelogenous leukaemia (CML), and the central role of protein tyrosine kinases in their pathogenesis have been identified. The hallmark for diagnosis of CML is demonstrating the presence of Philadelphia (Ph) chromosome in the bone marrow cells. This review provides an overview of the myeloproliferative neoplasms, their classification and their management.

Keywords

Myeloproliferative neoplasms Chronic myelogenous leukaemia Polycythaemia vera Primary myelofibrosis Essential thrombocythaemia 

References

  1. 1.
    Kilpivaara O, Levine RL. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Leukaemia. 2008;22(10):1813–7.CrossRefGoogle Scholar
  2. 2.
    Vainchenker W, Delhommeau F, Constntinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723–1735.CrossRefPubMedGoogle Scholar
  3. 3.
    Kico JM, Vij R, Kreisel FH, Hassan, Frater JL. Molecular pathology of myeloproliferative neoplasms. Am J Clin Pathol. 2010:133:602–615.  https://doi.org/10.1309/AJCPPPZIWFVGNE4A.
  4. 4.
    Wadleigh M, Teferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organisation criteria. Int J Hamatol. 2010;91(2(:174–9.CrossRefGoogle Scholar
  5. 5.
    Schmidt AE, Oh ST. Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Am J Clin Pathol. 2012;138(1):12–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Groffen J, Stephenson JR, Heisterkamp A, de Klein A, Bartram CR, Grosweld G. Philadelphia chromosome breakpoints are clustered on a limited region bar on chromosome 22. Cell. 1984:36(1):93–99.CrossRefPubMedGoogle Scholar
  7. 7.
    Mascarenhas J, Mughal TI, Verstosek S. Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. Curr Med Chem. 2012;19(26): 4399–413.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hermouet S, Bigot-Corbel E, Gardie B. Pathogenesis of myeloproliferative neoplasm: role and mechanisms of chronic inflammation. Mediators of Inflammation  https://doi.org/10.1155/2015/145293.
  9. 9.
    Kralovics R, Passmonti F, Buser AS, Teo SS, Tiedt LR, Passweg JR, et al. A gain-of-function mutation of JAK2in myeloproliferative disorder. NEJM. 2005;356(17):1779–1798.CrossRefGoogle Scholar
  10. 10.
    Schnittger S, Bacher U, Haferlach C, Dengler R, Krober A, Kern W, et al. Characterization of 35 new cases with four different MPL to 515 mutations in ET or PMF. Haematologica. 2009;94(1):141–144.CrossRefPubMedGoogle Scholar
  11. 11.
    Nangalia J, Massie CE, Baxter EJ, Nice Fl, Gundem G, Wedge DC, et al. Somatic CLAR mutation in myeloproliferative neoplasms with nonmutated AK2. NEJM. 2013;369(25):2391–2405.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Michiels JJ, Berneman Z, Schroyens W, De Raeve H. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 150 to Vainchenker 2005 and beyond. Acta Haematol. 2015;133(1):36–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Kurzrock R, Kantarjian HM, Druker BJ, Talpaz M. Philadelphia chromosome –positive leukaemias from basic and molecular therapeutics. Ann Intern Med. 2003;138:819–30.CrossRefPubMedGoogle Scholar
  14. 14.
    Goldman JM, Melo TW. The molecular biology of chronic myeloid leukaemia. Blood. 2003;96(10).Google Scholar
  15. 15.
    Oscier DG. Atypical chronic myeloid leukaemia: a distinct clinical entity related to the myelodysplastic syndrome. Haematol. 1996;92 (3):582–586.CrossRefGoogle Scholar
  16. 16.
    Kurzrock R, Bueso-Ramos CE, Kantarijian H, Freireich E, Tucker SL, Sicilliano M, et al. BCR rearrangement –negative chronic myelogenous leukaemia. Clin Oncol. 2001;19(11):2915–26.CrossRefGoogle Scholar
  17. 17.
    Jabbour E, Cortes J, Kantarjian H. Long term outcomes in the second –line treatment of chronic myeloid leukaemia: a review of tyrosine kinase inhibitors. Cancer. 2011;117(5):897–906.CrossRefPubMedGoogle Scholar
  18. 18.
    Gibson J, Iland HJ, Larsen SR, Brown CMS, Joshua DE. Leukaemias into the 21st century-part 2: the chronic leukaemia. Int Med J. 2013; 43: 484–494.CrossRefGoogle Scholar
  19. 19.
    Wong SF, Mirshahidi H. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners. Ann Pharmather. 2011;45(6):787–97.CrossRefGoogle Scholar
  20. 20.
    Anstrom KJ, Reed SD, Allen AS, Glendenning GA, Schulman KA. Long term survival estimates for Imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed Chronic-phase chronic myeloid leukaemia Cancer. 2004;101:2584–92.CrossRefPubMedGoogle Scholar
  21. 21.
    Finazzi G, Barbul T. How I treat patients with polycythaemia vera. Blood. 2007;109:no. 12 5104–5111.CrossRefPubMedGoogle Scholar
  22. 22.
    Besa GC, Woermann V. Polycythaemia vera. http://www.emedicine.com/MED/topic1864.htm.
  23. 23.
    Saini KS, Patnaik MM, Tefferi A. Polycythaemia associated pruritus and its management. Eur J Clin Invest. 2010;40(4):828–34.CrossRefPubMedGoogle Scholar
  24. 24.
    Patel RK, Lea N, Heneghan A, Westwood NB, Milojkovic D, Thanigalkumar M, et al. Prevalence of the activating JAL2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology. 2006;130:2031–2038.CrossRefPubMedGoogle Scholar
  25. 25.
    Fizzani G, Barbul T. Expertise-based management in essential thrombocythemia and polycythaemia vera. Cancer J. 2007;13(6):372–6.CrossRefGoogle Scholar
  26. 26.
    Mossuz P, Girodon F, Donnard M, Lattger-Cannard V, Dobo I, Boiret N, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica. 2004;89(10):1194–8.PubMedGoogle Scholar
  27. 27.
    Dessypris EN. Abnormal haematocrit in Internal Medicine Editor –in-Chief JW Stein Fifth edition, 1998, p 586, Mosby Inc, St Louis, Missouri.Google Scholar
  28. 28.
    Campbell PI, Green AR. The myeloproliferative disorders. NEJM. 2006;355:2452–2466.CrossRefPubMedGoogle Scholar
  29. 29.
    Tefferi A, Barbul T. bcc/abl negative classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005;80:1220–1232.CrossRefPubMedGoogle Scholar
  30. 30.
    Tefferi A. Polycythaemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc. 2003;76:174–194.CrossRefGoogle Scholar
  31. 31.
    Messinezy M, Pearson TC. ABC of clinical haematology. Clinical Review. BMJ. 1997;34:587.CrossRefGoogle Scholar
  32. 32.
    Penninga EI, Bjerrum OW. Polycythaemia vera and thrombocythaemia: current treatment and strategies. Drugs. 2006;66(17):2173–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Griesshammer M, Langer C. Pharmacotherapy of essential thrombocythaemia: economic consideration. Summary: Expert opinion in Pharmacotherapy. 2003;4:1499–1505.Google Scholar
  34. 34.
    Tefferi A. Myelofibrosis and myeloid metaplasia. NEJM. 2000;342(17):1255–1264.CrossRefPubMedGoogle Scholar
  35. 35.
    Kvasnicka HM, Thiele J, Werden C, et al. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer. 1997;80:707–719.CrossRefGoogle Scholar
  36. 36.
    Manoharan A. Myelofibrosis: Prognostic factors and treatment. Annotation. Brit J Haematol. 1988; 69: 295–298.CrossRefGoogle Scholar
  37. 37.
    Reilly JT, Snowden JA, Spearing RL, Fitzgerald PM, Jones N, Watmore A, et al. Cytogenetic abnormalities and their prognosis in idiopathic myelofibrosis: a study of 106 cases. Br J Haematol 1997;98:96–102.CrossRefPubMedGoogle Scholar
  38. 38.
    Manoharan A, Gemmell R, Brighton T, Dunkley S, Lopez K, Kyle P. Thrombosis and bleeding in myeloproliferative disorders: identification of at-risk patients with whole blood platelet aggregation studies. Br J Haematol. 1999;105:618–625.CrossRefPubMedGoogle Scholar
  39. 39.
    Bazargan A., Tam C. Janus kinase inhibitors in myeloproliferative neoplasms. Aust Prescriber. 2014;37:161–162.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations